The place of chemotherapy remains to be defined: recent results presented at the annual meeting of American Society of Clinical Oncology (ASCO) 2012 demonstrated a significant radiological PFS benefit and a strong trend in overall survival benefit of abiraterone plus prednisone over placebo plus predisone for patients with asymptomatic or mildly symptomatic mCRPC. 58 Other phase 3 studies exploring the impact of docetaxel based chemotherapy when used in earlier stage have shown positive biological PSA responses at the ASCO 2011 meeting. 59 – 61 Clinical events are strongly awaited.
← all excerpts
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
1
—
—